RapiDxFire™ Lyo-Flex 1-Step RT-qPCR 5X Master Mix
Designed with input from top molecular diagnostic assay manufacturers, the RapiDxFire Lyo-Flex 1-Step RT-qPCR 5x Master Mix supports the development of diagnostic devices and assays that meet healthcare provider and consumer demand for fast, accurate results. With consistent results in a liquid state at room temp or in a lyophilised state, this master mix will help you achieve predictable performance in unpredictable conditio…
RapiDxFire Lyo-Flex stands out from competitor mixes with an ideal combination of features and benefits.
- The unique heat-activated thermostable reverse transcriptase can withstand cDNA synthesis at high temperatures, enabling the detection of previously elusive viruses.
- 5x concentration creates an opportunity for higher test sensitivity while reducing waste.
- The master mix can detect RNA and DNA templates, making it ideal for viruses as well as bacteria.
- With an abundance of key PCR reaction components, this master mix supports the detection of multiple pathogens in a single reaction.
- The master mix remains stable in a broad range of temperatures and conditions, giving you more flexibility in shipping, storage, and automation setup.
- Lyophilize this master mix and bring PCR-based pathogen detection out of the lab.
Simplifying the journey from molecular diagnostic assay development to commercialization
Molecular diagnostics (MDx) is rapidly advancing, with a growing array of DNA- and RNA-based tests now available to physicians, pharmacists, geneticists, research scientists, and other healthcare professionals.
As labs work with human and microbial genes, test developers must comply with clinical guidelines and regulations. Both established companies and start-ups face challenges, including meeting regulatory standards, ensuring quality, and managing supply chain issues. Early planning and robust partnerships are key to overcoming these obstacles.
This essential guide explores these challenges through detailed case studies. It covers everything from early development and assay formulation, to supply chain security, offering expert insights on successfully bringing PCR, next-generation sequencing (NGS), and other nucleic acid-based diagnostic tests to market.
RapiDxFire Lyo-Flex 1-Step RT-qPCR 5X Master Mix
LGC demonstrates the analytical sensitivity and specificity of the RapiDxFire Lyo-Flex 1-Step RT-qPCR 5X Master Mix for both RNA and DNA genomes, its effectiveness at single-tube multiplexing in an MDx scenario, and the stability of the reaction components under various storage and handling conditions.
Pre- and post-lyophilization performance of RapiDxFire qPCR 5X Master Mix GF
In this application note, Biosearch Technologies and BioAcumen Global have partnered to demonstrate the performance of RapiDxFire qPCR 5X Master Mix GF pre- and post-lyophilization, using an African Swine Fever Virus (ASFV) detection assay (designed by BioAcumen Global).
The future of diagnostics: How innovators in molecular techniques are shaping healthcare
From enzymatics to informatics, Hillary Sullivan, Vice President of R&D at LGC Biosearch Technologies, shares her thoughts on some of the latest advancements in molecular diagnostics. With insights from successful partnerships in healthcare, Sullivan provides her perspective on what the most promising areas of scientific advancements might hold for this rapidly developing field in the next 25 years.
A revolution in diagnostics – The race for five-minute point-of-care PCR testing
Learn how UK-based diagnostics company, LEX Diagnostics, is working with LGC Biosearch Technologies to precipitate a step-change in PCR usability and speed





















